España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Actuate Therapeutics
ACTU
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$8.85
0.57
6.88%
Pre-Market: 6:59 AM EDT
Get Report
Comment
Actuate Therapeutics (ACTU) Forecast
News
Earnings
Actuate Therapeutics (ACTU) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Actuate Therapeutics (NASDAQ:ACTU) Stock
Actuate Therapeutics Stock (NASDAQ: ACTU)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, December 17, 2024
Actuate Therapeutics shares are trading highe...
Benzinga Newsdesk
Actuate Therapeutics Announces Interim Phase ...
Benzinga Newsdesk
Friday, December 13, 2024
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Tuesday, November 26, 2024
Actuate Therapeutics To Be Added To Russell 2...
Benzinga Newsdesk
Tuesday, November 12, 2024
Actuate Granted FDA Rare Pediatric Disease De...
Benzinga Newsdesk
Monday, September 23, 2024
Actuate Announces Scientific Reports Publicat...
Benzinga Newsdesk
Monday, September 16, 2024
Actuate Announces Upcoming Presentation On In...
Benzinga Newsdesk
Wednesday, September 11, 2024
Actuate Therapeutics Receives FDA Orphan Drug...
Benzinga Newsdesk
Monday, September 09, 2024
Actuate Therapeutics Says Elraglusib Demonstr...
Benzinga Newsdesk
Tuesday, August 13, 2024
Actuate Therapeutics Shares Opened For Trade ...
Benzinga Newsdesk
Trading Halt: Halt status updated at 10:35:00...
Benzinga Newsdesk
Reported Earlier, Actuate Therapeutics Prices...
Benzinga Newsdesk
Thursday, August 08, 2024
Actuate Therapeutics, Inc To Start Trading Tomorrow
Benzinga Insights
Wednesday, August 07, 2024
Actuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Benzinga Insights
Wednesday, July 24, 2024
Preview: Actuate Therapeutics, Inc Set To IPO Tomorrow
Benzinga Insights
Tuesday, July 23, 2024
Actuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Benzinga Insights
Tuesday, November 02, 2010
Actuate Reports Third Quarter 2010 Financial Results: EPS of $0.23
Benzinga
Monday, September 13, 2010
Benzinga's Top Upgrades (NOK, APOL, ERIC, ACTU)
Benzinga
Roth Capital Upgrades ACTU To Buy
Benzinga
Monday, August 02, 2010
Actuate Corporation Posts Solid Earnings (ACTU)
Benzinga
Monday, December 28, 2009
Actuate Corporation, RAM Energy Resources & The Finish Line Upgraded Today
Benzinga
Benzinga’s News Roundup (CALM, CGEN, VICL, TOBC, TEG, ACTU)
Benzinga
Monday, September 28, 2009
Needham Growth Is Buying Industrial And Retail Stocks
Benzinga
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
